Nelson Vergel
Founder, ExcelMale.com
Curated By Nelson Vergel | ExcelMale.com | Updated May 2026
For decades, the idea of giving testosterone to a man with a history of prostate cancer was considered medically reckless. The fear ran so deep that even men years past their surgery or radiation -- with undetectable PSA and no evidence of disease -- were routinely denied therapy for the debilitating symptoms of testosterone deficiency. That picture is changing. A growing body of clinical evidence, combined with a deeper biological understanding of how testosterone actually interacts with prostate tissue, is reshaping what's possible for survivors.
If you're a prostate cancer survivor struggling with chronic fatigue, lost libido, or erectile dysfunction and wondering whether TRT is permanently off the table, this article walks you through what the evidence actually says, who may be a candidate, and what rigorous monitoring looks like in practice.
What You Will Learn:
• Why the 'fuel to the fire' theory that dominated medicine for 80 years is now considered scientifically outdated
• What the Saturation Model explains about testosterone and prostate biology
• Which men with prostate cancer history may be candidates for TRT
• What current research -- including the SPIRIT Trial -- shows about recurrence risk
• What a rigorous monitoring protocol actually looks like
The problem? The foundational research was conducted before PSA testing existed, before reliable serum testosterone measurements were commercially available, and before modern pathological staging methods. The original observations came almost entirely from men who were at castrate-level testosterone -- a population where even small changes in androgen levels produce dramatic biological responses. Extrapolating that finding to all men with prostate cancer history, at all testosterone levels, turned out to be a significant scientific overreach.
Crucially, by 1965 Huggins himself suggested that 'hormonal excess might be used for therapeutic benefit' -- a revision the medical establishment largely ignored for four more decades.
Think of the prostate as a sponge. Once it is completely saturated, it cannot absorb another drop of water no matter how much more you pour over it. Similarly, once prostate androgen receptors are fully occupied, additional serum testosterone is essentially biological background noise.
Research by Marks et al. provided a pivotal data point: raising serum testosterone does not proportionally raise testosterone levels within the prostate tissue itself once the saturation point is reached. The prostate maintains an internal homeostatic mechanism that limits androgenic exposure regardless of what is happening systemically.
The practical implication: for any man whose testosterone is already above approximately 250 ng/dL, adding exogenous testosterone is unlikely to further stimulate prostate activity. The biological 'machinery' for androgen-driven growth is already running at full capacity.
A 2025 scoping review published in the International Journal of Impotence Research analyzed 12 studies from 2005 to 2025 and found that TRT was not associated with increased risk of biochemical recurrence or cancer progression in any included study. The review concluded that these findings challenge the historical belief that TRT poses an inherent oncologic risk to prostate cancer survivors.
A 2024 multi-institutional study by Flores and colleagues compared 198 TRT-treated post-prostatectomy patients with 5,001 controls and found a non-significantly decreased rate of biochemical recurrence in the TRT group (hazard ratio 0.84, 95% CI 0.48 to 1.46). A 2025 single-center study published in PMC evaluated men who remained hypogonadal following androgen deprivation therapy and radiation for locoregional prostate cancer, and found that TRT was not associated with clinically significant PSA elevation -- and documented no cases of prostate cancer recurrence.
Some data go further: certain surgical cohorts show that maintaining a eugonadal state after radical prostatectomy may be oncologically protective by preventing the selection of androgen-independent cancer cell lines -- the type most likely to resist future treatment.
The biological explanation is consistent with the Saturation Model: a chronically low androgen environment may select for androgen-independent cancer cell clones that are inherently more aggressive and harder to treat. Deliberately keeping men hypogonadal in the name of oncological caution may carry its own risks.
That said, none of this constitutes a definitive clearance. Long-term RCT data are still limited, and men considering TRT after prostate cancer must make this decision with incomplete long-term evidence -- and in genuine partnership with a knowledgeable physician.
Laboratory confirmation of testosterone deficiency is non-negotiable before initiating TRT. Two early-morning total testosterone measurements below 300 ng/dL are required, along with clinical symptoms -- low libido, fatigue, ED, or reduced muscle or bone mass. Approximately one-third of men in general practice lack this workup before starting TRT, a gap that is particularly unacceptable in the oncology setting.
What to Expect With PSA: If baseline testosterone is below the saturation point of approximately 250 ng/dL, some PSA increase is anticipated as levels normalize -- this is the 'PSA plateau effect.' A new stable PSA level should establish itself within three to six months. If PSA continues to rise beyond six months, or accelerates after initial stabilization, immediate investigation for recurrence is required. Any rise after initial plateau, or PSA above 0.1 ng/mL post-prostatectomy, triggers evaluation.
The rationale is nearly the inverse of conventional thinking: by 'shocking' resistant cancer cells with extreme hormonal fluctuation, BAT may sensitize them to existing therapies -- including enzalutamide and other agents they had developed resistance to. Preliminary studies suggest this may improve drug efficacy in some patients with mCRPC.
BAT is not standard care and is conducted only under institutional oversight in investigational settings. But it represents one of the most striking reversals in oncology thinking: the deliberate use of very high doses of testosterone as a potential therapeutic tool against the same disease that testosterone was once thought to exclusively promote. It further supports the conclusion that the 'testosterone is fuel' model was an oversimplification.
Participants received either 100 mg testosterone cypionate weekly or placebo for 12 weeks. The primary outcome is change in sexual activity; secondary outcomes include lean mass, energy, and mood. As of the most recent reported status, no PSA or clinical recurrence had been observed among randomized participants.
The SPIRIT Trial is small (142 participants) and of short duration (12 weeks). It cannot definitively determine long-term recurrence risk. But it fills a critical gap by providing the first placebo-controlled RCT safety signal in this population. A successful completion would likely push clinical guidelines toward broader acceptance of TRT in low-risk survivors.
Urologists have moved well ahead of formal label language. A survey of U.S. urologists found that 84 to 86% considered TRT safe for men who had undergone radiation or brachytherapy. In practice, data from the Optum database (2003 to 2018) found that only 2.4% of prostate cancer survivors received TRT after treatment -- peak usage hit 4.9% in 2013 before stabilizing around 1.8%. The men most likely to receive TRT were younger and more likely to have comorbid ED or depressive disorders.
TRT after prostate cancer treatment is not appropriate for everyone, and it is not risk-free. But for men with low-risk, organ-confined disease who have achieved sustained remission, the growing body of evidence supports it as a viable option -- provided monitoring is rigorous and the decision is made collaboratively with a knowledgeable urologist or men's health specialist.
For anyone navigating this intersection of hormone health and cancer survivorship, the ExcelMale community offers 20+ years of archived experience and physician-moderated discussion to help you ask better questions and advocate for more complete care.
2. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. European Urology. 2009;55:310-321. doi:10.1016/j.eururo.2008.09.024
3. Rastrelli G, Filippi S, Giovannini L, et al. Testosterone. Hormones and Cancer. 2013;4:179-195. doi:10.1007/s12672-013-0143-0
4. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296:2351-2361. doi:10.1001/jama.296.19.2351
5. Valderrábano RJ, Pencina K, Storer TW, et al. Testosterone replacement in prostate cancer survivors with testosterone deficiency: study protocol of a randomized controlled trial (SPIRIT Trial). Contemporary Clinical Trials. 2022;121:106897. doi:10.1016/j.cct.2022.106897
6. Flores J, et al. Oncologic outcomes of testosterone replacement therapy following radical prostatectomy: a multi-institutional comparative study. Presented at SUO Annual Meeting. 2024. urotoday.com summary
7. Kadomoto S, et al. Testosterone replacement therapy following definitive treatment for prostate cancer: a scoping review of safety and efficacy. International Journal of Impotence Research. 2025. doi:10.1038/s41443-025-01206-3
8. Shahine H, Zanaty M, Zakaria AS, et al. Testosterone Replacement Therapy in Hypogonadal Men with a Prostate Cancer Diagnosis: A British Society for Sexual Medicine Consensus Statement. World Journal of Men's Health. 2025. doi:10.5534/wjmh.250086
9. McCullough AN, et al. Testosterone therapy in patients with locoregional prostate cancer treated with prior androgen deprivation therapy and radiation: a retrospective single center review. Translational Andrology and Urology. 2025. PMC11921175
10. Jussila I, Ahtiainen JP, Laakkonen EK, et al. Testosterone levels at diagnosis: a key predictor of overall survival among patients with prostate cancer. BJC Reports. 2025. doi:10.1002/bco2.484
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. The information provided is not a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider -- including your urologist or oncologist -- before starting, modifying, or stopping any hormone therapy or medical treatment, especially if you have a personal history of prostate cancer.
About ExcelMale.com
ExcelMale.com is one of the longest-running men's health forums on the internet, with more than 24,000 registered members and over 20 years of archived discussion on testosterone replacement therapy, hormone optimization, sexual health, peptides, and longevity medicine. The forum is founded and moderated by Nelson Vergel -- chemical engineer, 34+ year TRT patient, and author of Testosterone: A Man's Guide and Beyond Testosterone. Nelson is also the founder of DiscountedLabs.com, which provides affordable direct-access lab testing for men optimizing their hormone health. The community exists to help men make better-informed decisions with the benefit of real-world experience, clinical research, and physician perspectives -- all in one place.
Visit ExcelMale.com
For decades, the idea of giving testosterone to a man with a history of prostate cancer was considered medically reckless. The fear ran so deep that even men years past their surgery or radiation -- with undetectable PSA and no evidence of disease -- were routinely denied therapy for the debilitating symptoms of testosterone deficiency. That picture is changing. A growing body of clinical evidence, combined with a deeper biological understanding of how testosterone actually interacts with prostate tissue, is reshaping what's possible for survivors.
If you're a prostate cancer survivor struggling with chronic fatigue, lost libido, or erectile dysfunction and wondering whether TRT is permanently off the table, this article walks you through what the evidence actually says, who may be a candidate, and what rigorous monitoring looks like in practice.
What You Will Learn:
• Why the 'fuel to the fire' theory that dominated medicine for 80 years is now considered scientifically outdated
• What the Saturation Model explains about testosterone and prostate biology
• Which men with prostate cancer history may be candidates for TRT
• What current research -- including the SPIRIT Trial -- shows about recurrence risk
• What a rigorous monitoring protocol actually looks like
Key Takeaways |
• The Saturation Model shows prostate tissue response to testosterone plateaus at approximately 230 to 260 ng/dL -- above this threshold, adding more testosterone does not further stimulate the prostate. • A 2025 scoping review of 12 studies found TRT was not associated with increased biochemical recurrence or cancer progression in men treated for localized prostate cancer. • Only 2.4% of prostate cancer survivors in U.S. databases received TRT between 2003 and 2018, despite many qualifying. • Short-acting formulations (gels or weekly injections) are required during the initial 3 to 6 month 'testosterone challenge' to allow rapid discontinuation if PSA rises. • Advanced, metastatic, or locally advanced untreated prostate cancer remains an absolute contraindication for TRT. • The SPIRIT Trial -- the first randomized, placebo-controlled RCT -- has reported no PSA or clinical recurrences among its participants to date. |
Why Did Doctors Fear Testosterone After Prostate Cancer for So Long?
The 'fuel to the fire' theory originated in 1941, when researchers Charles Huggins and Clarence Hodges demonstrated that surgical castration caused regression of metastatic prostate cancer, while exogenous testosterone appeared to stimulate it. This work earned Huggins the Nobel Prize in 1966 and the medical establishment treated the linear relationship between testosterone and cancer growth as settled science for the rest of the 20th century.The problem? The foundational research was conducted before PSA testing existed, before reliable serum testosterone measurements were commercially available, and before modern pathological staging methods. The original observations came almost entirely from men who were at castrate-level testosterone -- a population where even small changes in androgen levels produce dramatic biological responses. Extrapolating that finding to all men with prostate cancer history, at all testosterone levels, turned out to be a significant scientific overreach.
Crucially, by 1965 Huggins himself suggested that 'hormonal excess might be used for therapeutic benefit' -- a revision the medical establishment largely ignored for four more decades.
What Is the Saturation Model and Why Does It Explain TRT Risk Better?
The Saturation Model is the biological framework that finally explained why the linear androgen hypothesis did not hold up in clinical practice. Championed by Dr. Abraham Morgentaler at Harvard and supported by Rastrelli and colleagues, the model proposes that androgen receptors within the prostate tissue have a finite binding capacity. Once those receptors are 'saturated,' adding more testosterone to the bloodstream does not further stimulate prostate growth.Think of the prostate as a sponge. Once it is completely saturated, it cannot absorb another drop of water no matter how much more you pour over it. Similarly, once prostate androgen receptors are fully occupied, additional serum testosterone is essentially biological background noise.
Research by Marks et al. provided a pivotal data point: raising serum testosterone does not proportionally raise testosterone levels within the prostate tissue itself once the saturation point is reached. The prostate maintains an internal homeostatic mechanism that limits androgenic exposure regardless of what is happening systemically.
Researcher & Year | Identified Saturation Threshold | Key Finding |
Rastrelli et al. (2013) | 230 to 260 ng/dL total testosterone | PSA response plateaus once this threshold is reached; no further stimulation observed above it. |
Morgentaler et al. (2014) | Above 250 ng/dL | Double-blind, placebo-controlled study: no significant PSA variation in men with baseline T above 250 ng/dL given testosterone gel. |
Marks et al. | Saturation point (intra-prostatic) | Raising serum testosterone does not raise intra-prostatic testosterone levels once saturation is reached. |
The practical implication: for any man whose testosterone is already above approximately 250 ng/dL, adding exogenous testosterone is unlikely to further stimulate prostate activity. The biological 'machinery' for androgen-driven growth is already running at full capacity.
Does TRT Increase the Risk of Prostate Cancer Coming Back?
This is the question every survivor and every urologist wants answered definitively. While large-scale, long-term randomized controlled trial data are still accumulating, the observational and retrospective literature has grown substantially -- and its message is consistently reassuring for well-selected patients.A 2025 scoping review published in the International Journal of Impotence Research analyzed 12 studies from 2005 to 2025 and found that TRT was not associated with increased risk of biochemical recurrence or cancer progression in any included study. The review concluded that these findings challenge the historical belief that TRT poses an inherent oncologic risk to prostate cancer survivors.
A 2024 multi-institutional study by Flores and colleagues compared 198 TRT-treated post-prostatectomy patients with 5,001 controls and found a non-significantly decreased rate of biochemical recurrence in the TRT group (hazard ratio 0.84, 95% CI 0.48 to 1.46). A 2025 single-center study published in PMC evaluated men who remained hypogonadal following androgen deprivation therapy and radiation for locoregional prostate cancer, and found that TRT was not associated with clinically significant PSA elevation -- and documented no cases of prostate cancer recurrence.
Some data go further: certain surgical cohorts show that maintaining a eugonadal state after radical prostatectomy may be oncologically protective by preventing the selection of androgen-independent cancer cell lines -- the type most likely to resist future treatment.
The Androgen Paradox: Is Low Testosterone Actually More Dangerous?
One of the most counterintuitive findings in this literature is the relationship between low testosterone and prostate cancer aggressiveness. Multiple studies have found that men with the lowest baseline testosterone levels are more likely to be diagnosed with high-grade, aggressive cancers (Gleason 4+3 or higher). A 2025 Finnish study by Jussila and colleagues found that testosterone levels at diagnosis were a significant predictor of overall survival in prostate cancer patients.The biological explanation is consistent with the Saturation Model: a chronically low androgen environment may select for androgen-independent cancer cell clones that are inherently more aggressive and harder to treat. Deliberately keeping men hypogonadal in the name of oncological caution may carry its own risks.
That said, none of this constitutes a definitive clearance. Long-term RCT data are still limited, and men considering TRT after prostate cancer must make this decision with incomplete long-term evidence -- and in genuine partnership with a knowledgeable physician.
Who Is a Candidate for TRT After Prostate Cancer Treatment?
Not every man with a prostate cancer history is a candidate. Risk stratification is essential. The current evidence base supports TRT consideration in a specific subset of well-selected men -- and absolute contraindications remain for others.Risk Category | Clinical Profile | Current Recommendation |
Optimal Candidates | Organ-confined disease (pT2, N0, M0), Gleason score below 7 (3+4 or lower), undetectable PSA below 0.1 ng/mL for at least one year post-surgery | TRT may be considered after meeting required cure interval with informed consent and monitoring plan |
Post-Radiation Candidates | Stable PSA following EBRT or brachytherapy; no evidence of disease recurrence | TRT may be considered; data are more limited than surgical cohort; highest vigilance required |
Active Surveillance | Untreated low-risk cancer (Gleason 3+3 or 3+4), under AS protocol | Some urologists consider TRT appropriate with annual biopsies for first 2 years; shared decision-making essential |
Absolute Contraindication | Advanced, metastatic, locally advanced untreated disease, mHSPC, mCRPC outside of investigational BAT protocol | TRT is strictly contraindicated and may significantly worsen prognosis |
Laboratory confirmation of testosterone deficiency is non-negotiable before initiating TRT. Two early-morning total testosterone measurements below 300 ng/dL are required, along with clinical symptoms -- low libido, fatigue, ED, or reduced muscle or bone mass. Approximately one-third of men in general practice lack this workup before starting TRT, a gap that is particularly unacceptable in the oncology setting.
Why Formulation Choice Matters in the First Six Months
Current expert guidance recommends starting with short-acting formulations during the first three to six months -- often called the 'testosterone challenge' period. Transdermal gels or weekly testosterone cypionate injections allow for rapid discontinuation if PSA rises unexpectedly. Transitioning to long-acting formulations such as testosterone undecanoate or subcutaneous pellets should happen only after a stable PSA plateau is established.What Monitoring Protocol Is Required After Starting TRT?
Surveillance is not optional -- it is the mechanism that makes TRT safe after prostate cancer treatment. Missing labs is not a low-stakes oversight in this population.Test or Procedure | Frequency: Year 1 | Frequency: Thereafter |
PSA measurement | Every 3 to 4 months | At least twice annually |
Hematocrit and hemoglobin | 2 to 4 times per year | At least 1 to 2 times per year |
Digital rectal exam (DRE) | 1 to 2 times (RT cohort) | Annually |
Prostate biopsy (active surveillance only) | Annually for first 2 years of TRT | Standard AS schedule if no progression |
What to Expect With PSA: If baseline testosterone is below the saturation point of approximately 250 ng/dL, some PSA increase is anticipated as levels normalize -- this is the 'PSA plateau effect.' A new stable PSA level should establish itself within three to six months. If PSA continues to rise beyond six months, or accelerates after initial stabilization, immediate investigation for recurrence is required. Any rise after initial plateau, or PSA above 0.1 ng/mL post-prostatectomy, triggers evaluation.
What Is Bipolar Androgen Therapy for Advanced Prostate Cancer?
For men with metastatic castration-resistant prostate cancer (mCRPC), a radically different approach called Bipolar Androgen Therapy (BAT) is under investigation. BAT involves cycling between supraphysiological testosterone doses and castrate-level androgen deprivation, aiming to disrupt the adaptive survival mechanisms that resistant cancer cells develop in chronically low-androgen environments.The rationale is nearly the inverse of conventional thinking: by 'shocking' resistant cancer cells with extreme hormonal fluctuation, BAT may sensitize them to existing therapies -- including enzalutamide and other agents they had developed resistance to. Preliminary studies suggest this may improve drug efficacy in some patients with mCRPC.
BAT is not standard care and is conducted only under institutional oversight in investigational settings. But it represents one of the most striking reversals in oncology thinking: the deliberate use of very high doses of testosterone as a potential therapeutic tool against the same disease that testosterone was once thought to exclusively promote. It further supports the conclusion that the 'testosterone is fuel' model was an oversimplification.
What Does the SPIRIT Trial Tell Us About TRT Safety in Prostate Cancer Survivors?
The SPIRIT Trial (Surviving Prostate Cancer while Improving the Quality of Life through Rehabilitation with Testosterone) is the first randomized, placebo-controlled, double-blind trial investigating TRT in prostate cancer survivors. Conducted at Brigham and Women's Hospital and led by Dr. Shalender Bhasin's team, it enrolled 142 men who had undergone radical prostatectomy for organ-confined disease (Gleason below 7, stage pT2, N0, M0) with undetectable PSA for more than two years.Participants received either 100 mg testosterone cypionate weekly or placebo for 12 weeks. The primary outcome is change in sexual activity; secondary outcomes include lean mass, energy, and mood. As of the most recent reported status, no PSA or clinical recurrence had been observed among randomized participants.
The SPIRIT Trial is small (142 participants) and of short duration (12 weeks). It cannot definitively determine long-term recurrence risk. But it fills a critical gap by providing the first placebo-controlled RCT safety signal in this population. A successful completion would likely push clinical guidelines toward broader acceptance of TRT in low-risk survivors.
What Is the Current Guideline Landscape?
A real-world tension exists between what the evidence shows and what official guidelines say. The FDA still carries a warning listing prostate cancer as a contraindication for testosterone therapy, while the AUA acknowledges insufficient evidence for the 'fuel to the fire' theory and notes that many urologists already consider TRT appropriate for low-risk survivors. In 2025, the British Society for Sexual Medicine published a consensus statement supporting TRT as a safe and effective option for appropriately selected hypogonadal men following prostate cancer treatment.Urologists have moved well ahead of formal label language. A survey of U.S. urologists found that 84 to 86% considered TRT safe for men who had undergone radiation or brachytherapy. In practice, data from the Optum database (2003 to 2018) found that only 2.4% of prostate cancer survivors received TRT after treatment -- peak usage hit 4.9% in 2013 before stabilizing around 1.8%. The men most likely to receive TRT were younger and more likely to have comorbid ED or depressive disorders.
Frequently Asked Questions
Will TRT cause my PSA to rise after prostate cancer surgery?
Some PSA increase can occur if your baseline testosterone is below the saturation point (~250 ng/dL), as normalizing testosterone partially stimulates any remaining prostatic epithelial activity. This should stabilize within three to six months. A PSA that continues rising beyond six months, or accelerates after initial stabilization, warrants immediate evaluation for recurrence.How long after a prostatectomy should I wait before considering TRT?
Current expert recommendations suggest waiting at least one year after surgery with undetectable PSA (below 0.1 ng/mL) throughout that period. Most men in retrospective datasets started TRT an average of 1.5 years post-surgery; for radiation patients the average was 2.6 years.Can men on active surveillance use TRT?
Some experienced urologists offer TRT to men on active surveillance for low-risk prostate cancer, with close monitoring including annual biopsies in the first two years. The evidence is more limited than for post-surgical survivors, and the decision requires careful shared decision-making with your urologist.Does low testosterone increase prostate cancer risk?
Counterintuitively, the evidence increasingly links low testosterone to higher-grade, more aggressive prostate cancer. This 'androgen paradox' does not mean TRT is protective for everyone, but it challenges the old assumption that more testosterone automatically correlates with worse oncological outcomes.What formulation of testosterone is preferred after prostate cancer treatment?
Short-acting formulations -- transdermal gels or weekly intramuscular or subcutaneous injections -- are the standard starting point. They allow rapid discontinuation if PSA rises unexpectedly. Long-acting formulations (subcutaneous pellets, undecanoate) should only be considered after a stable PSA plateau is established over at least six months.Related ExcelMale Forum Discussions
Thread | What You Will Find |
SPIRIT Trial: TRT in Prostate Cancer Survivors | Full study protocol and discussion of the first randomized controlled trial of TRT in post-prostatectomy survivors. |
How Testosterone Therapy in Prostate Cancer Has Evolved | Compilation of urologist perspectives and evolving clinical opinion on TRT after prostate cancer treatment. |
Dr. Morgentaler Debunks Myths About Testosterone and Prostate Cancer | Dr. Abraham Morgentaler's detailed breakdown of the old dogma, the Saturation Model, and what men should ask their doctors. |
Restoring Balance: Exploring Testosterone Replacement in Prostate Cancer | Community discussion on the growing evidence supporting TRT for select patients following cancer treatment. |
The Death of the 'Testosterone Causes Prostate Cancer' Myth | In-depth article and forum discussion examining why the historical ban on TRT is no longer supported by evidence. |
Testosterone Therapy Today: Clinical Advances and Safety with Dr. Morgentaler | Dr. Morgentaler reviews modern treatment options and discusses TRT in men with a prostate cancer history. |
Testosterone Hysteria: An Interview with Abraham Morgentaler, MD | Classic ExcelMale interview in which Dr. Morgentaler addresses the FDA, lawyers, and the media's distortion of testosterone risk. |
How Lizard Sex Transformed Medicine (Morgentaler's Story) | The biographical background of Dr. Morgentaler's career-long effort to overturn the Nobel Prize-winning prostate cancer dogma. |
Conclusion
The story of testosterone and prostate cancer is one of medicine correcting itself at scale. An 80-year-old dogma built on pre-PSA-era research -- and extrapolated far beyond its evidence base -- is being replaced by a nuanced, biology-grounded framework that allows well-selected survivors to restore vitality without sacrificing oncological safety.TRT after prostate cancer treatment is not appropriate for everyone, and it is not risk-free. But for men with low-risk, organ-confined disease who have achieved sustained remission, the growing body of evidence supports it as a viable option -- provided monitoring is rigorous and the decision is made collaboratively with a knowledgeable urologist or men's health specialist.
For anyone navigating this intersection of hormone health and cancer survivorship, the ExcelMale community offers 20+ years of archived experience and physician-moderated discussion to help you ask better questions and advocate for more complete care.
Key References
1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research. 1941;1:293-297.2. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. European Urology. 2009;55:310-321. doi:10.1016/j.eururo.2008.09.024
3. Rastrelli G, Filippi S, Giovannini L, et al. Testosterone. Hormones and Cancer. 2013;4:179-195. doi:10.1007/s12672-013-0143-0
4. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296:2351-2361. doi:10.1001/jama.296.19.2351
5. Valderrábano RJ, Pencina K, Storer TW, et al. Testosterone replacement in prostate cancer survivors with testosterone deficiency: study protocol of a randomized controlled trial (SPIRIT Trial). Contemporary Clinical Trials. 2022;121:106897. doi:10.1016/j.cct.2022.106897
6. Flores J, et al. Oncologic outcomes of testosterone replacement therapy following radical prostatectomy: a multi-institutional comparative study. Presented at SUO Annual Meeting. 2024. urotoday.com summary
7. Kadomoto S, et al. Testosterone replacement therapy following definitive treatment for prostate cancer: a scoping review of safety and efficacy. International Journal of Impotence Research. 2025. doi:10.1038/s41443-025-01206-3
8. Shahine H, Zanaty M, Zakaria AS, et al. Testosterone Replacement Therapy in Hypogonadal Men with a Prostate Cancer Diagnosis: A British Society for Sexual Medicine Consensus Statement. World Journal of Men's Health. 2025. doi:10.5534/wjmh.250086
9. McCullough AN, et al. Testosterone therapy in patients with locoregional prostate cancer treated with prior androgen deprivation therapy and radiation: a retrospective single center review. Translational Andrology and Urology. 2025. PMC11921175
10. Jussila I, Ahtiainen JP, Laakkonen EK, et al. Testosterone levels at diagnosis: a key predictor of overall survival among patients with prostate cancer. BJC Reports. 2025. doi:10.1002/bco2.484
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. The information provided is not a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider -- including your urologist or oncologist -- before starting, modifying, or stopping any hormone therapy or medical treatment, especially if you have a personal history of prostate cancer.
About ExcelMale.com
ExcelMale.com is one of the longest-running men's health forums on the internet, with more than 24,000 registered members and over 20 years of archived discussion on testosterone replacement therapy, hormone optimization, sexual health, peptides, and longevity medicine. The forum is founded and moderated by Nelson Vergel -- chemical engineer, 34+ year TRT patient, and author of Testosterone: A Man's Guide and Beyond Testosterone. Nelson is also the founder of DiscountedLabs.com, which provides affordable direct-access lab testing for men optimizing their hormone health. The community exists to help men make better-informed decisions with the benefit of real-world experience, clinical research, and physician perspectives -- all in one place.
Visit ExcelMale.com
